Engel Julian, Lategahn Jonas, Rauh Daniel
Faculty of Chemistry and Chemical Biology, TU Dortmund University , Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany.
ACS Med Chem Lett. 2015 Dec 18;7(1):2-5. doi: 10.1021/acsmedchemlett.5b00475. eCollection 2016 Jan 14.
In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clinical outcomes. However, the emergence of a newly discovered acquired drug resistance challenges the concept of small molecule targeted cancer therapy in NSCLC.
在过去五年中，对于如何克服非小细胞肺癌（NSCLC）中T790M耐药性的深入理解，最终促成了具有出色临床疗效的第三代共价表皮生长因子受体（EGFR）抑制剂的研发。然而，新发现的获得性耐药的出现，对NSCLC中小分子靶向癌症治疗的理念提出了挑战。
